Welcome, Guest. Please login or register.
August 24, 2019, 12:18:52 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 54312
  • Total Topics: 4602
  • Online Today: 60
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 39
Total: 39

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Gilead’s Selonsertib Shows Promise as Treatment for NASH  (Read 4203 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 635
    • Hep Mag
Gilead’s Selonsertib Shows Promise as Treatment for NASH
« on: January 11, 2017, 10:13:48 am »
Gilead Sciences’ selonsertib (formerly GS-4997) improved various measures of liver disease severity among individuals with non-alcoholic steatohepatitis (NASH) and moderate to severe liver fibrosis in a recent midrange trial regardless of whether the drug was given with simtuzumab (SIM).
 
Researchers conducted a randomized, open-label Phase II trial of selonsertib alone or in combination with SIM among 72 people with NASH and fibrosis stages F2 (25 people) or F3 (47 people). Participants were randomized 2 to 2 to 1 to 1 to 1 to receive 24 weeks of 6 milligrams of the investigational apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib, 18 mg of selonsertib, 6 mg of selonsertib plus 125 mg of the monoclonal antibody SIM, 18 mg of selonsertib plus 125 mg of SIM or 125 mg of SIM. Selonsertib was given orally once a day, while SIM was given weekly through a subcutaneous injection (into the fat just below the skin).

For more information...
https://www.hepmag.com/article/gileads-selonsertib-shows-promise-treatment-nash

 


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.